PTLF (Petlife Pharmaceuticals) Graham Number: $N/A (As of Feb. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Petlife Pharmaceuticals Graham Number?

Petlife Pharmaceuticals PTLF Graham Number is $N/A as of Feb. 2018.

Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.

As of today (2026-08-16), the stock price of Petlife Pharmaceuticals is $0.0001. Petlife Pharmaceuticals's graham number for the quarter that ended in Feb. 2018 was $N/A. Therefore, Petlife Pharmaceuticals's Price to Graham Number ratio for today is N/A.

The historical rank and industry rank for Petlife Pharmaceuticals's Graham Number or its related term are showing as below:

PTLF's Price-to-Graham-Number is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.595
* Ranked among companies with meaningful Price-to-Graham-Number only.

Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.


Petlife Pharmaceuticals  (OTCPK:PTLF) Graham Number Explanation

Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:

Current price should not be more than 15 times average earnings of the past three years.

Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)

Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.

In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.

Petlife Pharmaceuticals's Price to Graham number Ratio for today is calculated as

Price to Graham number=Share Price (Today)/Graham number (Q: Feb. 2018 )
=0.0001/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Please keep these in mind:

1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.


Petlife Pharmaceuticals Graham Number Related Terms


Petlife Pharmaceuticals Graham Number Historical Data

* Premium members only.

The historical data trend for Petlife Pharmaceuticals's Graham Number can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Petlife Pharmaceuticals Graham Number Chart

Petlife Pharmaceuticals Annual Data
Trend Aug08 Aug09 Aug10 Aug11 Aug12 Aug13 Aug14 Aug15 Aug16 Aug17
Graham Number
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Petlife Pharmaceuticals Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Graham Number Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PTLF vs PCYN, YBAO, BKIT: Graham Number Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Petlife Pharmaceuticals's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Petlife Pharmaceuticals Price-to-Graham-Number vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Petlife Pharmaceuticals's Price-to-Graham-Number distribution charts can be found below:

* The bar in red indicates where Petlife Pharmaceuticals's Price-to-Graham-Number falls into.



Petlife Pharmaceuticals Graham Number Calculation

Graham Number is a concept based on Ben Graham's conservative valuation of companies.

Petlife Pharmaceuticals's Graham Number for the fiscal year that ended in Aug. 2017 is calculated as

Graham Number
=sqrt of (22.5* Tangible Book per Share *EPS without NRI)
=sqrt of (22.5*-0.019*-0.323)
=N/A

Petlife Pharmaceuticals's Graham Number for the quarter that ended in Feb. 2018 is calculated as

Graham Number
=sqrt of (22.5*Tangible Book per Share*EPS without NRI (TTM))
=sqrt of (22.5*-0.025*-0.046)
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Graham Number →
What does a Graham Number of $N/A mean?
Petlife Pharmaceuticals (PTLF) has a Graham Number of $N/A as of Feb. 2018. The Graham Number values a company based on its per-share earnings and book value. View historical data on Petlife Pharmaceuticals and its competitors.
Is Petlife Pharmaceuticals' Graham Number too high?
Petlife Pharmaceuticals' current Graham Number is $N/A.
How does Petlife Pharmaceuticals' Graham Number compare to PCYN and YBAO?
Petlife Pharmaceuticals' Graham Number of $N/A can be compared against companies in the Drug Manufacturers industry. The industry median Graham Number is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Drug Manufacturers company?
The median Graham Number among Drug Manufacturers companies is 1.60, based on 598 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on Petlife Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Graham Number is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petlife Pharmaceuticals's current Graham Number is $N/A. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petlife Pharmaceuticals stock overvalued right now?
Petlife Pharmaceuticals (PTLF) has a current Graham Number of $N/A. The current Graham Number is $N/A. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For Petlife Pharmaceuticals (PTLF), the current Graham Number is $N/A as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Petlife Pharmaceuticals Business Description

Address 38 West Main Street, 6th Floor, Hancock, MD, USA, 21750
Petlife Pharmaceuticals Inc specializes in the research, development, sales, and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases such as arthritis. It develops potentiated veterinary cancer medications and nutraceuticals, under its tradename Vitalzul based on Escozine formula. The Vitalzul is a polarized, bioactive peptide extracted from the Blue Caribbean Scorpion (Rhopularus Princeps), which contains amino acids, proteins, and minerals.